   
 |
Apolipoprotein D in schizophrenia. Mahadik, 2002.
Significantly Reduced Docosahexaenoic and Docosapentaenoic Acid Concentrations in Erythrocyte Membranes from Schizophrenic Patients. Assies, 2001.
Cerebral metabolism in male patients with schizophrenia. Puri, 2003.
Controlled Study of Ethyl-EPA.Supplemental Treatment in Schizophrenia. Emsley, 2002.
Decreased antioxidant enzymes and membrane PUFAs.in schizophrenic and bipolar mood disorder patients. Ranjekar, 2003.
Essential Polyunsaturated Fatty Acid and Lipid Peroxide Levels in Never-Medicated and Medicated Schizophrenia Patients. Arvindakshan, 2003.
Exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. Peet, 2002.
A
Placebo-Controlled Trial of Omega-3 Fatty Acid (Ethyl Eicosapentaenoic
Acid) Supplementation for Residual Symptoms and Cognitive Impairment in
Schizophrenia. Fenton, 2001.
Smoking, Gender, and Dietary Influences on Erythrocyte Essential Fatty Acid Composition among Patients with Schizophrenia or Schizoaffective Disorder. Hibbeln, 2003.
Lipid metabolism, human evolution and schizophrenia. Horrobin, 1999.
Supplementation with a combination of N-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Arvindakshan, 2003.
The metabolic syndrome, omega-3 fatty acids and inflammatory processes in relation to schizophrenia. Peet, 2006.
A volumetric biochemical niacin flush-based index that noninvasively detects fatty acid deficiency in schizophrenia. Puri, 2002.
Niacin skin-flush response and electrodermal activity in patients with schizophrenia and healthy controls. Nilsson, 2006.
Nutrition and Schizophrenia. Peet, 2005.
Double-blind studies of EPA in schizophrenia. Peet, 2001.
Membrane Phospholipid Abnormalities of Basal Ganglia in Never-Treated Schizophrenia:. Jayakumar, 2003.
The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental
concept of schizophrenia. Horrobin, 1998.
Gene targets related to phospholipid and fatty acid metabolism in schizophrenia and other psychiatric disorders: an update. Bennett, 2000.
Essential fatty acids: theoretical aspects and treatment implications for schizophrenia and depression. Peet, 2002.
Red cell and
plasma fatty acid changes accompanying symptom remission in a patient
with schizophrenia treated with eicosapentaenoic acid. Richardson, 2000.
Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient. Su, 2001.
Thiobarbituric acid reactive substances in the cerebrospinal fluid in schizophrenia. Skinner, 2005.
The metabolic syndrome, omega-3 fatty acids and inflammatory processes in relation to schizophrenia. Peet, 2006.
The role of phospholipases A2 in schizophrenia. Law, 2006.
|
* The material on this web site is for informational
purposes only.
|
Schizophrenia Papers